Literature DB >> 10189216

Communicating risk reductions. Researchers should present results with both relative and absolute risks.

A Edwards, G Elwyn, N Stott.   

Abstract

Mesh：

Year:  1999        PMID： 10189216

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

Review 1.  Understanding risk and lessons for clinical risk communication about treatment preferences.

Authors:  A Edwards; G Elwyn
Journal:  Qual Health Care       Date:  2001-09

2.  Lifetime risks for cardiovascular disease mortality by cardiorespiratory fitness levels measured at ages 45, 55, and 65 years in men. The Cooper Center Longitudinal Study.

Authors:  Jarett D Berry; Benjamin Willis; Sachin Gupta; Carolyn E Barlow; Susan G Lakoski; Amit Khera; Anand Rohatgi; James A de Lemos; William Haskell; Donald M Lloyd-Jones
Journal:  J Am Coll Cardiol       Date:  2011-04-12       Impact factor: 24.094

3.  Patients prefer pictures to numbers to express cardiovascular benefit from treatment.

Authors:  Felicity Goodyear-Smith; Bruce Arroll; Lydia Chan; Rod Jackson; Sue Wells; Timothy Kenealy
Journal:  Ann Fam Med       Date:  2008 May-Jun       Impact factor: 5.166

Review 4.  Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales.

Authors:  Dianne C Berry; D K Raynor; Peter Knapp; Elisabetta Bersellini
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

5.  American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

Authors:  Kala Visvanathan; Rowan T Chlebowski; Patricia Hurley; Nananda F Col; Mary Ropka; Deborah Collyar; Monica Morrow; Carolyn Runowicz; Kathleen I Pritchard; Karen Hagerty; Banu Arun; Judy Garber; Victor G Vogel; James L Wade; Powel Brown; Jack Cuzick; Barnett S Kramer; Scott M Lippman
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

6.  Length of time periods in treatment effect descriptions and willingness to initiate preventive therapy: a randomised survey experiment.

Authors:  Erik Berglund; Ragnar Westerling; Johan Sundström; Per Lytsy
Journal:  BMC Med Inform Decis Mak       Date:  2018-11-20       Impact factor: 2.796
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.